Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 13/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 8/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27788342 | 0.98 | SLC5A2 (0.46) | SLC5A2MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27788263 | 0.94 | SLC5A2 (0.44) | SLC5A2MEN1KMT2ASMN1; SMN2KDM4E | |
| Magnesium Chloride Anhydrous SCHEMBL29084875 | 0.94 | SLC5A2 (0.44) | SLC5A2MEN1KMT2ASMN1; SMN2KDM4E | |
| Chlorolithium SCHEMBL29084967 | 0.92 | SLC5A2 (0.42) | SLC5A2MEN1KMT2ASMN1; SMN2KDM4E | |
| Chlorolithium SCHEMBL29084912 | 0.92 | SLC5A2 (0.42) | SLC5A2MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL29041345 | 0.84 | SLC5A2 (0.35) | SLC5A2MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL16601002 | 0.78 | SLC5A2 (0.45) | SLC5A2SMN1; SMN2KDM4ESLC5A1LMNA | |
| SCHEMBL3622807 | 0.78 | MEN1 (0.66) | SLC5A2MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27820545 | 0.77 | SLC5A2 (0.35) | SLC5A2SLC5A1 | |
| SCHEMBL7785329 | 0.77 | NQO1 (0.56) | SMN1; SMN2KDM4EHPGDDHFRNQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328100-B2 | Process for the preparation of β-C-arylglucosides | SCINOPHARM TAIWAN, LTD. (TW) | 2016-05-03 | — | — | US | claimed |
| WO-2015155739-A1 | PROCESS FOR THE PREPARATION OF BETA-C-ARYLGLUCOSIDES | SCINOPHARM TAIWAN, LTD. (TW) | 2015-10-15 | — | — | WO | claimed |
| US-20150291569-A1 | PROCESS FOR THE PREPARATION OF beta-C-ARYLGLUCOSIDES | SCINOPHARM TAIWAN, LTD. (TW) | 2015-10-15 | — | — | US | claimed |
| CN-108675976-B | 6-halogenated glucose carbon glycoside and preparation method and application thereof | 浙江宏元药业股份有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-104619713-B | Oxabicyclo derivative, preparation method and applications | 四川海思科制药有限公司 | 2017-06-16 | — | — | CN | disclosed |
| US-9328100-B2 | Process for the preparation of β-C-arylglucosides | SCINOPHARM TAIWAN, LTD. (TW) | 2016-05-03 | — | — | US | disclosed |
| CN-103450214-B | Glucopyranosyl derivatives, its preparation method and in application pharmaceutically | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-04-06 | — | — | CN | disclosed |
| CN-103450214-B | Glucopyranosyl derivatives, its preparation method and in application pharmaceutically | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-04-06 | — | — | CN | disclosed |
| US-20150291569-A1 | PROCESS FOR THE PREPARATION OF beta-C-ARYLGLUCOSIDES | SCINOPHARM TAIWAN, LTD. (TW) | 2015-10-15 | — | — | US | disclosed |
| EP-2895490-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-07-22 | — | — | EP | disclosed |
| WO-2015043511-A1 | GLUCOPYRANOSYL DERIVATIVES AND THEIR USES IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-04-02 | — | — | WO | disclosed |
| CN-102112483-A | Solid forms of (2S,3R,4R,5S,6R) -2- (4-chloro-3- (4-ethoxybenzyl) phenyl) -6- (methylthio) tetrahydro-2H-pyran-3, 4, 5-triol and methods of use thereof | LEXICON PHARMACEUTICALS INC | 2011-06-29 | — | — | CN | disclosed |
| CN-101801989-A | Methods and compounds for the preparation of sodium-glucose cotransporter 2 inhibitors | LEXICON PHARMACEUTICALS INC | 2010-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291569-A1 | PROCESS FOR THE PREPARATION OF beta-C-ARYLGLUCOSIDES | GANC, UGCG, UGGT1 | SLC5A2 68/4885MEN1 3880/4885KMT2A 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.